PSMA Ligands for PET-Imaging of Prostate Cancer.

Related Articles

PSMA Ligands for PET-Imaging of Prostate Cancer.

J Nucl Med. 2017 Jul 07;:

Authors: Schwarzenböck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Afshar-Oromieh A, Herrmann K, Eiber M

Abstract
Targeting the prostate-specific membrane antigen (PSMA) with (68)Ga-labelled and (18)F-labelled PET-agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer (PC) has been established as a widely accepted clinical indication for PSMA ligand PET/CT in many parts of the world due to the results of multiple, primarily retrospective, studies that indicate superior detection efficacy compared to standard of care imaging. For high-risk primary PC, evidence is growing that this modality significantly aids in the detection of otherwise occult nodal and bone metastases. For both clinical indications in recurrent as well as in primary prostate cancer, preliminary data demonstrate a substantial impact on clinical management. Emerging data imply that intraprostatic tumor localization, therapy stratification, and treatment monitoring of advanced disease in specific clinical situations might become future indications. Current criteria for image reporting of PSMA ligand PET are evolving given the expanding body of literature on physiologic and pathologic uptake patterns and pitfalls. This CME article intends to give an educational overview on the current status of PSMA ligand PET imaging including imaging procedure and interpretation, clinical indications, diagnostic potential, and impact on treatment planning.

PMID: 28687599 [PubMed - as supplied by publisher]

from #ENT-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2tZO8VB